Tumor budding: a prognostic factor in rectal cancer
Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v3i4.4855
Abstract
Tumor budding (TB) is the presence of isolated tumor cells located in the infiltrating front of the tumor. Objective: to determine if the presence of TB is associated with other histopathological factors of poor RC prognosis such as lymph node involvement, tumor size greater than 5 cm, configuration of the infiltrative tumor margin, vasculolymphatic and perineural invasion, as well as determining whether the presence of TB influences the disease-free period. Results: 89 patients were evaluated, only 25 met inclusion and exclusion criteria, the average age was 56.52 years, men were more affected (56%), the RAB (72%), was the surgery, as used followed by RAP (24 %), and EP (4%). The distribution according to TNM: stage I (32%), 7 IIIB (28%), 4 IIIC (16%), 3 IIA (12%), 2 IIB (8%) and 1 IIIA (4%). 56% of patients N0, 44% N1. Tumor size: 36% tumors between 1 and 2 cm, 32% between 2.5 and 3.5 cm, 28% between 4 and 5 cm, 4% greater than 5 cm. Tumor invasion pattern: 64% had an infiltrating pattern, while 36% had an expansive pattern. Distribution of TB: Bd1 44%, Bd2 28% and Bd3 28%. 28% of the patients presented relapses, more frequent in the first 24 months. Disease-Free Survival (DFS) was evidenced in terms of irrigation groups TB, Bd1 of 76 months, Bd2 of 60 months, Bd3 of 20 months. TB is a prognostic factor associated with decreased disease-free survival in rectal cancer.
Keywords
tumor budding; rectal carcinoma; tumor invasion pattern
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Cogorno Wasylkowski L y colaboradores. Indicación de cistectomía precoz en el cáncer vesical no músculo infiltrante. Revisión de la literatura. Actas Urol Esp. 2017.
[2] Jiménez J, Luque R, Gaforio J, Delgado M. Valor pronóstico del patrón de invasión tumoral en el cáncer colorrectal esporádico. Cir Esp. 2005;77(6):337- 42.
[3] El Gendi S, Al-Gendi S. Assessment of tumor budding in colorectal carcinoma: Correlation with b-catenin nuclear expression. Journal of the Egyptian National Cancer Institute 2011 23: 1–9.
[4] Mitrovic B, Schaeffer D, Riddel R, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology 2012; 25: 1315–1325.
[5] Peña J, Briceño J, Parada D, Medina S, Pezzetti L, Rodríguez A. C-erbB-2 correlación con pronóstico y sobrevida en el adenocarcinoma de colon Rev Venez Oncol 2007;19(1):20-29.
[6] Labalde M, Labrador F, Golitsin A, Pinto S, Carlin J, García J. Tumor budding y el cáncer colorrectal. Rev Chil Cir. 2014; 66(6):556-561.
[7] Jass J, Ajioka Y, Allen J, Chan Y, Cohen R, Nixon J. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopatology. 1996;28:543-548.
[8] Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology 2017;00:1–13.
[9] Horcic M, Koelzer V, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology 2012.
[10]Graham R, Vierkant R, Tillmans L, Wang A, Laird A, Weisenberger D, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of PrognosticSignificance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol. 2015 October ; 39(10): 1340–1346.
[2] Jiménez J, Luque R, Gaforio J, Delgado M. Valor pronóstico del patrón de invasión tumoral en el cáncer colorrectal esporádico. Cir Esp. 2005;77(6):337- 42.
[3] El Gendi S, Al-Gendi S. Assessment of tumor budding in colorectal carcinoma: Correlation with b-catenin nuclear expression. Journal of the Egyptian National Cancer Institute 2011 23: 1–9.
[4] Mitrovic B, Schaeffer D, Riddel R, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology 2012; 25: 1315–1325.
[5] Peña J, Briceño J, Parada D, Medina S, Pezzetti L, Rodríguez A. C-erbB-2 correlación con pronóstico y sobrevida en el adenocarcinoma de colon Rev Venez Oncol 2007;19(1):20-29.
[6] Labalde M, Labrador F, Golitsin A, Pinto S, Carlin J, García J. Tumor budding y el cáncer colorrectal. Rev Chil Cir. 2014; 66(6):556-561.
[7] Jass J, Ajioka Y, Allen J, Chan Y, Cohen R, Nixon J. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopatology. 1996;28:543-548.
[8] Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology 2017;00:1–13.
[9] Horcic M, Koelzer V, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology 2012.
[10]Graham R, Vierkant R, Tillmans L, Wang A, Laird A, Weisenberger D, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of PrognosticSignificance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol. 2015 October ; 39(10): 1340–1346.
Copyright © 2026 Luis Fagúndez, Héctor González, Wladimir Villegas, Saúl Vieira, Carlos Núñez, Pedro Márquez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License